Literature DB >> 17060525

Posaconazole prophylaxis in experimental systemic zygomycosis.

Francesco Barchiesi1, Elisabetta Spreghini, Alfredo Santinelli, Annette W Fothergill, Eleonora Pisa, Daniele Giannini, Michael G Rinaldi, Giorgio Scalise.   

Abstract

Three isolates of zygomycetes belonging to two different genera (Rhizopus oryzae and Absidia corymbifera) were used to produce a systemic infection in neutropenic mice. On days -2 and -1 and at 2 h prior to infection, the mice received either posaconazole (POS) at doses ranging from 20 to 80 mg/kg of body weight/day or amphotericin B (AMB) at 1 mg/kg/day. Antifungal drug efficacy was assessed by determination of the prolongation of survival, determination of the percentage of infected organs (brain, lung, spleen, and kidney), and histological examination for the number of infection foci and their sizes in brain and kidney tissues. AMB significantly prolonged the survival of mice infected with all isolates. POS significantly prolonged the survival of mice infected with zygomycetes. Cultured organs from mice infected with R. oryzae were all positive, while treated mice challenged with A. corymbifera generally showed lower percentages of infected organs compared with the percentages for the controls. Zygomycete isolates established an active infection (the presence of hyphae) in the brains and the kidneys of all controls. In mice challenged with R. oryzae, both antifungal drugs were effective at reducing the number and the size of infection foci in the kidneys. Only AMB reduced the numbers, but not the sizes, of infection foci in the brain. Finally, both drugs significantly reduced the numbers and the sizes of infection foci in both tissues of mice infected with A. corymbifera. Our data suggest that prophylaxis with POS has some potential to prevent zygomycosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060525      PMCID: PMC1797686          DOI: 10.1128/AAC.00969-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice.

Authors:  Mason X Zhang; M Charlotte Bohlman; Carol Itatani; Dennis R Burton; Paul W H I Parren; Stephen C St Jeor; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models.

Authors:  F C Odds; F Van Gerven; A Espinel-Ingroff; M S Bartlett; M A Ghannoum; M V Lancaster; M A Pfaller; J H Rex; M G Rinaldi; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

3.  Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.

Authors:  Ashraf S Ibrahim; Joel C Bowman; Valentina Avanessian; Keturah Brown; Brad Spellberg; John E Edwards; Cameron M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

4.  Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

Authors:  Issam I Raad; John R Graybill; Ana Beatriz Bustamante; Oliver A Cornely; Veronica Gaona-Flores; Claude Afif; Donald R Graham; Richard N Greenberg; Susan Hadley; Amelia Langston; Ricardo Negroni; John R Perfect; Punnee Pitisuttithum; Angela Restrepo; Gary Schiller; Lisa Pedicone; Andrew J Ullmann
Journal:  Clin Infect Dis       Date:  2006-05-08       Impact factor: 9.079

Review 5.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

Review 6.  Posaconazole.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Factors determining the susceptibility of mice to experimental phycomycosis.

Authors:  M J Corbel; S M Eades
Journal:  J Med Microbiol       Date:  1975-11       Impact factor: 2.472

8.  Observations on the localization of Absidia corymbifera in vivo.

Authors:  M J Corbel; S M Eades
Journal:  Sabouraudia       Date:  1978-06

9.  Activity of posaconazole in treatment of experimental disseminated zygomycosis.

Authors:  Eric Dannaoui; Jacques F G M Meis; David Loebenberg; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

10.  Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

Authors:  Jo-Anne H van Burik; Roberta S Hare; Howard F Solomon; Michael L Corrado; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2006-02-21       Impact factor: 9.079

View more
  8 in total

1.  Lichtheimia corymbifera Colonization Leading to Pulmonary Infection Can Be Prevented with Liposomal Amphotericin B in a New Murine Model.

Authors:  Thomas Brunet; Kévin Brunet; Grégory Jouvion; Estelle Cateau; Sandrine Marchand; Blandine Rammaert
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.

Authors:  M Mar Rodríguez; F Javier Pastor; Deanna A Sutton; Enrique Calvo; Annette W Fothergill; Valentina Salas; Michael G Rinaldi; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

Review 3.  Antifungal pharmacokinetics and pharmacodynamics.

Authors:  Alexander J Lepak; David R Andes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

4.  Anidulafungin in combination with amphotericin B against Aspergillus fumigatus.

Authors:  Elisabetta Spreghini; Fiorenza Orlando; Alfredo Santinelli; Eleonora Pisa; Cristian Loretelli; Esther Manso; Maria Eleonara Milici; Giorgio Scalise; Francesco Barchiesi
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

5.  Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.

Authors:  Susanne Perkhofer; Maria Locher; Manuel Cuenca-Estrella; Reinhard Rüchel; Reinhard Würzner; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

6.  Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae.

Authors:  M Mar Rodríguez; Carolina Serena; Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

Review 7.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors:  Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

Review 8.  Pharmacokinetics and Pharmacodynamics of Posaconazole.

Authors:  Lu Chen; Elke H J Krekels; Paul E Verweij; Jochem B Buil; Catherijne A J Knibbe; Roger J M Brüggemann
Journal:  Drugs       Date:  2020-05       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.